Send a Tweet
Most Popular Choices
Share on Facebook 6 Share on Twitter Printer Friendly Page More Sharing
Best Web OpEds    H4'ed 9/15/15

"America's Most Admired Lawbreaker", by Steven Brill

Quicklink Submitted By   No comments
Message James Quandy
Over The Course Of 20 Years, Johnson & Johnson Created A Powerful Drug, Promoted It Illegally To Children And The Elderly, Covered Up The Side Effects And Made Billions Of Dollars. This Is The Inside Story.

Johnson & Johnson has already settled thousands of cases involving illicit promotion of Risperdal, including Department of Justice civil and criminal complaints, for a total fast approaching $3 billion.

But on the morning of the analysts’ meeting, the company was still manning the battle stations with squadrons of lawyers fighting off another 4,200 cases, apparently willing to risk a few more bad verdicts while hoping to weed out the weakest cases and wear the opposition down in order to save on final settlement costs of the strongest claims.



Read the rest of the story HERE:

At highline.huffingtonpost.com
Valuable 1  
Rate It | View Ratings

James Quandy Social Media Pages: Facebook page url on login Profile not filled in       Twitter page url on login Profile not filled in       Linkedin page url on login Profile not filled in       Instagram page url on login Profile not filled in

Former small business owner now retired.

Related Topic(s): ; ; ; ; , Add Tags
Go To Commenting
The views expressed herein are the sole responsibility of the author and do not necessarily reflect those of this website or its editors.
Writers Guidelines

 
Contact EditorContact Editor
Support OpEdNews

OpEdNews depends upon can't survive without your help.

If you value this article and the work of OpEdNews, please either Donate or Purchase a premium membership.

STAY IN THE KNOW
If you've enjoyed this, sign up for our daily or weekly newsletter to get lots of great progressive content.
Daily Weekly     OpEd News Newsletter
Name
Email
   (Opens new browser window)
 

To View Comments or Join the Conversation:

Tell A Friend